MedTrace Logo

A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris

NCT02604680 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 509

Last updated 2017-07-28

No results posted yet for this study

Summary

The objective of the study is to compare the safety and efficacy of multiple formulations of BLI1100 to a control group and placebo in treating patients with moderate-severe acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

BLI1100-1

BLI1100-1 Topical gel

DRUG

BLI1100-2

BLI1100-2 Topical gel

DRUG

BLI1100-3

BLI1100-3 Topical gel

DRUG

BLI1100-4

BLI1100-4 Topical gel

DRUG

Placebo

Placebo - Topical gel

Sponsors & Collaborators

  • Braintree Laboratories

    lead INDUSTRY

Principal Investigators

  • John McGowan · Braintree Laboratories, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02604680 on ClinicalTrials.gov